bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo
Authors: Liu Yi , Cao Yanyan , Zhang Weihe , Bergmeier Stephen , Qian Yanrong , Akbar Huzoor , Colvin Robert , Ding Juan , Tong Lingying , Wu Shiyong , Hines Jennifer , Chen Xiaozhuo
Published: April 2023

PDF file, 70KB, WZB117 inhibited cell proliferation of cancer cells more than non-cancerous cells and exhibited synergy with anticancer drugs.
Supplementary Methods and Figure Legend from Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Authors: Clark Caroline C. , Weitzel Jeffrey N. , O'Connor Timothy R.
Published: April 2023

PDF file, 176K.
Supplementary Figure 2 from Reversing Effect of Ring Finger Protein 43 Inhibition on Malignant Phenotypes of human Hepatocellular Carcinoma
Authors: Xing Chunyang , Zhou Wuhua , Ding Songming , Xie Haiyang , Zhang Wu , Yang Zhe , Wei Bajin , Chen Kangjie , Su Rong , Cheng Jun , Zheng Shusen , Zhou Lin
Published: April 2023

PDF file - 204K, Effects of siRNAs on RNF43 mRNA expression. HepG2 and SMMC-7721 cells were transfected with RNF43 siRNAs (RNF43-si1, -si2, and -si3), negative control siRNAs (siNC), or Mock-transfected (Mock). RNF43 mRNA expression was measured by qRT-PCR 48 hours after transfection.
Supplementary Figure 5 from Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
Authors: Clark Caroline C. , Weitzel Jeffrey N. , O'Connor Timothy R.
Published: April 2023

PDF file, 240K, SUPPLEMENTARY FIGURE S5. RAD51 foci formed in cells as a function of BRCA status after treatment with ABT-888/carboplatin. All RAD51 foci were analyzed by immunostaining after cells were treated with drugs for 24 h. (A) HCC1937 and HCC1937+BRCA1 treated with vehicle or 200 μM ABT-888/25 μM carboplatin. (B) EUFA423 and EUFA423+BRCA2 treated with vehicle or 12.5 μM ABT-888/12.5 μM carboplatin.
Supplementary Figure 4 from Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation
Authors: Kim Sun Mi , Kwon Oh-Joon , Hong Yun Kyoung , Kim Joo Hang , Solca Flavio , Ha Sang-Jun , Soo Ross A. , Christensen James G. , Lee Ji Hyun , Cho Byoung Chul
Published: April 2023

PDF file, 29K, Effect of JAK2 knockdown on afatinib-induced cell cytotoxicity.
Supplementary Figure 1 from Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation
Authors: Kim Sun Mi , Kwon Oh-Joon , Hong Yun Kyoung , Kim Joo Hang , Solca Flavio , Ha Sang-Jun , Soo Ross A. , Christensen James G. , Lee Ji Hyun , Cho Byoung Chul
Published: April 2023

PDF file, 104K, Effects of afatinib on cell cycle and cell death.
Supplementary Figure 4 from Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2′-Deoxycytidine in Solid Tumor Cells
Authors: Venturelli Sascha , Berger Alexander , Weiland Timo , Essmann Frank , Waibel Michaela , Nuebling Tina , Häcker Sabine , Schenk Martin , Schulze-Osthoff Klaus , Salih Helmut R. , Fulda Simone , Sipos Bence , Johnstone Ricky W. , Lauer Ulrich M. , Bitzer Michael
Published: April 2023

PDF file - 104K, 5-aza-CR induces a decrease of p53 protein levels, whereas 5-aza-dC increases -galactosidase in various tumor entities.
Supplementary Figure 3 from Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2′-Deoxycytidine in Solid Tumor Cells
Authors: Venturelli Sascha , Berger Alexander , Weiland Timo , Essmann Frank , Waibel Michaela , Nuebling Tina , Häcker Sabine , Schenk Martin , Schulze-Osthoff Klaus , Salih Helmut R. , Fulda Simone , Sipos Bence , Johnstone Ricky W. , Lauer Ulrich M. , Bitzer Michael
Published: April 2023

PDF file - 18K, p53 expression of HepG2 and Hep3B cells.
Supplemental Figure 2 from A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits Tumor Growth
Authors: Fontenot Emily , Rossi Emma , Mumper Russell , Snyder Stephanie , Siamakpour-Reihani Sharareh , Ma Ping , Hilliard Eleanor , Bone Bradley , Ketelsen David , Santos Charlene , Patterson Cam , Klauber-DeMore Nancy
Published: April 2023

Activity ELISA for the purified monoclonal antibody to SFRP2 for "Peptide B".
Supplemental Figure 1 from A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits Tumor Growth
Authors: Fontenot Emily , Rossi Emma , Mumper Russell , Snyder Stephanie , Siamakpour-Reihani Sharareh , Ma Ping , Hilliard Eleanor , Bone Bradley , Ketelsen David , Santos Charlene , Patterson Cam , Klauber-DeMore Nancy
Published: April 2023

Western blot of protein lysates from 2H11 endothelial cells, SVR angiosarcoma cells, MDA-MB-231 breast cancer cells, and negative control medial probing for SFRP2.
Supplementary Methods, Figure Legends 1-3, Table Legends 1 from A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothened Antagonists
Authors: Chenna Venugopal , Hu Chaoxin , Pramanik Dipankar , Aftab Blake T. , Karikari Collins , Campbell Nathaniel R. , Hong Seung-Mo , Zhao Ming , Rudek Michelle A. , Khan Saeed R. , Rudin Charles M. , Maitra Anirban
Published: April 2023

PDF file - 111K
Supplementary Figure 2 from A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity
Authors: Weldon John E. , Xiang Laiman , Zhang Jingli , Beers Richard , Walker Dawn A. , Onda Masanori , Hassan Raffit , Pastan Ira
Published: April 2023

PDF file - 605K, Relative cytotoxicity in vitro
Supplementary Table 2 from Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
Authors: Orcutt Kelly Davis , Rhoden John J. , Ruiz-Yi Benjamin , Frangioni John V. , Wittrup K. Dane
Published: April 2023

PDF file, 61KB, Tabular values of biodistribution for pretargeted 177Lu-DOTA-Bn, 177Lu-DOTA, 111In-DOTA-Bn, and 111In-DOTA.
Supplementary Table 1 from Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
Authors: Orcutt Kelly Davis , Rhoden John J. , Ruiz-Yi Benjamin , Frangioni John V. , Wittrup K. Dane
Published: April 2023

PDF file, 54KB, Model parameters and citations for estimates.
Supplementary Figure 3 from Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
Authors: Orcutt Kelly Davis , Rhoden John J. , Ruiz-Yi Benjamin , Frangioni John V. , Wittrup K. Dane
Published: April 2023

PDF file, 91KB, 177Lu-DOTA Organ/tissue biodistribution.
Supplementary Figure 2 from Effect of Small-Molecule–Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody
Authors: Orcutt Kelly Davis , Rhoden John J. , Ruiz-Yi Benjamin , Frangioni John V. , Wittrup K. Dane
Published: April 2023

PDF file, 65KB, Biodistribution of clearing agent.
Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Authors: Kalous Ondrej , Conklin Dylan , Desai Amrita J. , O'Brien Neil A. , Ginther Charles , Anderson Lee , Cohen David J. , Britten Carolyn D. , Taylor Ian , Christensen James G. , Slamon Dennis J. , Finn Richard S.
Published: April 2023

PDF file, 55K.
Supplementary Methods and Figure Legends from microRNA-9 Targets Matrix Metalloproteinase 14 to Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells
Authors: Zhang Huanyu , Qi Meng , Li Shiwang , Qi Teng , Mei Hong , Huang Kai , Zheng Liduan , Tong Qiangsong
Published: April 2023

PDF file, 37KB.
Supplementary Figure 4 from microRNA-9 Targets Matrix Metalloproteinase 14 to Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells
Authors: Zhang Huanyu , Qi Meng , Li Shiwang , Qi Teng , Mei Hong , Huang Kai , Zheng Liduan , Tong Qiangsong
Published: April 2023

PDF file, 201KB, Scratch migration assay of NB cells.
Supplementary Figure 3 from Attenuation of Argininosuccinate Lyase Inhibits Cancer Growth via Cyclin A2 and Nitric Oxide
Authors: Huang Hau-Lun , Hsu Hui-Ping , Shieh Shu-Chu , Chang Yung-Sheng , Chen Wei-Ching , Cho Chien-Yu , Teng Chiao-Fang , Su Ih-Jen , Hung Wen-Chun , Lai Ming-Derg
Published: April 2023

PDF - 1437 KB, Knockdown of ASL by shAsl111 inhibits cell growth in vitro
Supplementary Figure 2 from Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters
Authors: Kim KyoungHyun , Chadalapaka Gayathri , Pathi Satya S. , Jin Un-Ho , Lee Ju-Seog , Park Yun-Yong , Cho Sung-Gook , Chintharlapalli Sudhakar , Safe Stephen
Published: April 2023

PDF file, 220K, Role of E2F in modulating miR expression.
Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Authors: Kani Kian , Faca Vitor M. , Hughes Lindsey D. , Zhang Wenxuan , Fang Qiaojun , Shahbaba Babak , Luethy Roland , Erde Jonathan , Schmidt Joanna , Pitteri Sharon J. , Zhang Qing , Katz Jonathan E. , Gross Mitchell E. , Plevritis Sylvia K. , McIntosh Martin W. , Jain Anjali , Hanash Samir , Agus David B. , Mallick Parag
Published: April 2023

PDF file, 47KB, Protein Identification for Solid Phase Extraction of Glycoproteins (SPEG)with 16 hours of gefitinib treatment.
Supplementary Figure 4 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Authors: Kani Kian , Faca Vitor M. , Hughes Lindsey D. , Zhang Wenxuan , Fang Qiaojun , Shahbaba Babak , Luethy Roland , Erde Jonathan , Schmidt Joanna , Pitteri Sharon J. , Zhang Qing , Katz Jonathan E. , Gross Mitchell E. , Plevritis Sylvia K. , McIntosh Martin W. , Jain Anjali , Hanash Samir , Agus David B. , Mallick Parag
Published: April 2023

PDF file, 131KB, Basal levels protein biomarkers. Basal levels of EpCAM, ELAVL1, and CBFB demonstrate a correlation to gefitinib sensitivity. Non-treated NSCLC lysates, synchronized by serum starvation for 16 hours, were generated and assayed for basal protein levels by Western blot.
Supplementary Figure S3 from miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR
Authors: Xu Chuanliang , Zeng Qinsong , Xu Weidong , Jiao Li , Chen Yanqiong , Zhang Zhensheng , Wu Chengyao , Jin Taile , Pan Anyin , Wei Rongchao , Yang Bo , Sun Yinghao
Published: April 2023

PDF file - 546KB, Relative mTOR mRNA expression was assayed in EJ, 5637 and J82 cells after being transfected with pre-miR-100 precursor, miR-100 inhibitor or corresponding control RNA duplex.
Supplementary Figure S1 from miRNA-100 Inhibits Human Bladder Urothelial Carcinogenesis by Directly Targeting mTOR
Authors: Xu Chuanliang , Zeng Qinsong , Xu Weidong , Jiao Li , Chen Yanqiong , Zhang Zhensheng , Wu Chengyao , Jin Taile , Pan Anyin , Wei Rongchao , Yang Bo , Sun Yinghao
Published: April 2023

PDF file - 77KB, The fold-changes in miR-100 was confirmed by qRT-PCR, relative to the control as 1, as a consequence of either up-regulating after infection with miR-100-expressing lentivirus/vector control lentivirus(EJ and 5637) or down-regulating after transfected by miR-100 inhibitor/control RNA oligo(J82 and HT-1376).
Supplementary Figure 3 from Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
Authors: Samon Jeremy B. , Castillo-Martin Mireia , Hadler Michael , Ambesi-Impiobato Alberto , Paietta Elisabeth , Racevskis Janis , Wiernik Peter H. , Rowe Jacob M. , Jakubczak John , Randolph Sophia , Cordon-Cardo Carlos , Ferrando Adolfo A.
Published: April 2023

PDF file, 306KB, Interaction between PF-03084014 and chemotherapeutic agents.
Supplementary Figure Legends 1-5 from MUC13 Mucin Augments Pancreatic Tumorigenesis
Authors: Chauhan Subhash C. , Ebeling Mara C. , Maher Diane M. , Koch Michael D. , Watanabe Akira , Aburatani Hiroyuki , Lio Yuhlong , Jaggi Meena
Published: April 2023

PDF file - 110K
Supplementary Figure 2 from MUC13 Mucin Augments Pancreatic Tumorigenesis
Authors: Chauhan Subhash C. , Ebeling Mara C. , Maher Diane M. , Koch Michael D. , Watanabe Akira , Aburatani Hiroyuki , Lio Yuhlong , Jaggi Meena
Published: April 2023

PDF file - 1.2MB
Supplementary Figure 1 from MUC13 Mucin Augments Pancreatic Tumorigenesis
Authors: Chauhan Subhash C. , Ebeling Mara C. , Maher Diane M. , Koch Michael D. , Watanabe Akira , Aburatani Hiroyuki , Lio Yuhlong , Jaggi Meena
Published: April 2023

PDF file - 6.1MB
Supplementary Figure 3 from Immunotherapy for Hepatoma Using a Dual-Function Vector with Both Immunostimulatory and Pim-3–Silencing Effects
Authors: Guo Qie , Lan Peixiang , Yu Xin , Han Qiuju , Zhang Jian , Tian Zhigang , Zhang Cai
Published: April 2023

PDF - 135K, Figure S3. Treatment with bi-functional vector promotes lymphocyte infiltration and tumor necrosis in tumor tissues. A. Tumor tissues were analyzed by H&E staining. The yellow arrows show lymphocyte infiltration, and the white arrows show necrosis in tumor tissues. Magnification: x 200. B. Tumor apoptosis was analyzed by TUNEL staining. C. Serum levels of IFN-alpha and IFN-beta after treatment were detected by ELISA.
Supplementary Figure 1 from HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
Authors: Penuel Elicia , Li Congfen , Parab Vaishali , Burton Luciana , Cowan Kyra J. , Merchant Mark , Yauch Robert L. , Patel Premal , Peterson Amy , Hampton Garret M. , Lackner Mark R. , Hegde Priti S.
Published: April 2023

PDF file - 22K, Changes in shed Met do not correlate with changes in cHGF over the duration of the first cycle of onartuzumab administration in the Phase 1A study.
Supplementary Figures 1 - 4 from Therapeutic Inhibition of Jak Activity Inhibits Progression of Gastrointestinal Tumors in Mice
Authors: Stuart Emma , Buchert Michael , Putoczki Tracy , Thiem Stefan , Farid Ryan , Elzer Joachim , Huszar Dennis , Waring Paul M. , Phesse Toby J. , Ernst Matthias
Published: April 2023

PDF file - 1978K, Supplementary Figure 1: The gpA33 locus confers expression of tamoxifen-activatable CreERT2 transgene to the metaplastic epithelium of gastric tumors of gp130F/F mice. Supplementary Figure 2: AZD1480-treatment reduces gastric tumour burden in gp130F/F mice. Supplementary Figure 3: Immunohistochemical analysis of gastric tumors from AZD1480-treated gp130F/F mice. Supplementary Figure 4: Systemic AZD1480 administration reduces established colitis-associated colon cancer burden in wild-type mice.
Supplementary Tables 1 - 6, Figures 1 - 4 from Drug Repurposing for Gastrointestinal Stromal Tumor
Authors: Pessetto Ziyan Y. , Weir Scott J. , Sethi Geetika , Broward Melinda A. , Godwin Andrew K.
Published: April 2023

PDF file - 1279K, Table S1: List of FDA-approved drug library; Table S2: Screen parameters; Table S3: Curve classification criteria; Table S4: Screening of FDA-approved drugs on Hs 919.T. cell line hits summary; Table S5: Drug structures of candidate hits; Table S6: Known pharmacological data of auranofin (Prometheus Laboratories Inc. (San Diego, CA, USA); Figure S1: Drug screen assay development; Figure S2: TrxR1, TrxR2, TrxR3 transcript expression analysis from a GIST microarray dataset GS31802; Figure S3: In vitro effects of auranofin treatment on TrxR/Trx activity; Figure S4: GIST-T1, GIST T1-10R, and GIST 882 cells were treated with or without auranofin at the concentration indicated in the figure.
Supplemental Figure 4 from CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Authors: Chen Robert , Hou Jessie , Newman Edward , Kim Young , Donohue Cecile , Liu Xueli , Thomas Sandra H. , Forman Stephen J. , Kane Susan E.
Published: April 2023

Supplemental Figure 4. Immunohistochemistry for PgP on HL patient biopsy.
Supplemental Figure 1 from CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Authors: Chen Robert , Hou Jessie , Newman Edward , Kim Young , Donohue Cecile , Liu Xueli , Thomas Sandra H. , Forman Stephen J. , Kane Susan E.
Published: April 2023

Supplemental Figure 1. Karpas-R cultured in the absence of BV regains CD30-positivity.
Supplementary Figure 1 from Cyclin G–Associated Kinase Is Necessary for Osteosarcoma Cell Proliferation and Receptor Trafficking
Authors: Susa Michiro , Choy Edwin , Liu Xianzhe , Schwab Joseph , Hornicek Francis J. , Mankin Henry , Duan Zhenfeng
Published: April 2023

Supplementary Figure 1 from Cyclin G–Associated Kinase Is Necessary for Osteosarcoma Cell Proliferation and Receptor Trafficking
Supplementary Figure 1 from Smac Mimetics in Combination with TRAIL Selectively Target Cancer Stem Cells in Nasopharyngeal Carcinoma
Authors: Wu Man-si , Wang Guang-feng , Zhao Zhi-qiang , Liang Yi , Wang Heng-bang , Wu Miao-yi , Min Ping , Chen Li-zhen , Feng Qi-sheng , Bei Jin-xin , Zeng Yi-xin , Yang Dajun
Published: April 2023

PDF file - 1054K, Figure S1. Photographs of colony and sphere formation assay of S18 and S26 cells.
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
Authors: Cho Hee-Yeon , Wang Weijun , Jhaveri Niyati , Lee David Jungpa , Sharma Natasha , Dubeau Louis , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

Supplementary Figure 2. Quantitative evaluation of the effects of NEO212 on cytotoxicity
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
Authors: Cho Hee-Yeon , Wang Weijun , Jhaveri Niyati , Lee David Jungpa , Sharma Natasha , Dubeau Louis , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

Supplementary Figure 4. NEO212 induces DNA damage in TMZ-sensitive and TMZ-resistant cells
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
Authors: Cho Hee-Yeon , Wang Weijun , Jhaveri Niyati , Lee David Jungpa , Sharma Natasha , Dubeau Louis , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

Supplementary Figure 5. U251 TR-resistant and LN229 TR2-resistant cells are MGMT-negative
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
Authors: Cho Hee-Yeon , Wang Weijun , Jhaveri Niyati , Lee David Jungpa , Sharma Natasha , Dubeau Louis , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

Supplementary Figure 6. PARP inhibitor is not cytotoxic to U251 cells
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
Authors: Cho Hee-Yeon , Wang Weijun , Jhaveri Niyati , Lee David Jungpa , Sharma Natasha , Dubeau Louis , Schönthal Axel H. , Hofman Florence M. , Chen Thomas C.
Published: April 2023

Supplementary Figure 7. Pathological evaluation of tissues following chronic treatment of NEO212
Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
Authors: Parnell K. Mark , Foulks Jason M. , Nix Rebecca N. , Clifford Adrianne , Bullough Jeremy , Luo Bai , Senina Anna , Vollmer David , Liu Jihua , McCarthy Virgil , Xu Yong , Saunders Michael , Liu Xiao-Hui , Pearce Scott , Wright Kevin , O'Reilly Marc , McCullar Michael V. , Ho Koc-Kan , Kanner Steven B.
Published: April 2023

Supplementary Figure Legends - PDF file 41K, Legends for supplemental figures 1-4
Supplementary Figure 1 from Comparing Histone Deacetylase Inhibitor Responses in Genetically Engineered Mouse Lung Cancer Models and a Window of Opportunity Trial in Patients with Lung Cancer
Authors: Ma Tian , Galimberti Fabrizio , Erkmen Cherie P. , Memoli Vincent , Chinyengetere Fadzai , Sempere Lorenzo , Beumer Jan H. , Anyang Bean N. , Nugent William , Johnstone David , Tsongalis Gregory J. , Kurie Jonathan M. , Li Hua , DiRenzo James , Guo Yongli , Freemantle Sarah J. , Dragnev Konstantin H. , Dmitrovsky Ethan
Published: April 2023

PDF file - 652K, Supplemental Fig. 1: The structure of vorinostat (SAHA).
Supplementary Table 3 from Coleusin Factor, a Novel Anticancer Diterpenoid, Inhibits Osteosarcoma Growth by Inducing Bone Morphogenetic Protein-2–Dependent Differentiation
Authors: Geng Shuo , Sun Bo , Lu Ran , Wang Jingze
Published: April 2023

PDF - 64K, Cell cycle distribution of MG-63 cells.
Supplementary Figure 1 from Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
Authors: Rozan Caroline , Cornillon Amélie , Pétiard Corinne , Chartier Martine , Behar Ghislaine , Boix Charlotte , Kerfelec Brigitte , Robert Bruno , Pèlegrin André , Chames Patrick , Teillaud Jean-Luc , Baty Daniel
Published: April 2023

PDF file - 60K, Lack of competition between bsFab and human IgG for FcγRIIIa binding.
Supplementary Data from Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer
Authors: Pal Krishnendu , Cao Ying , Gaisina Irina N. , Bhattacharya Santanu , Dutta Shamit K. , Wang Enfeng , Gunosewoyo Hendra , Kozikowski Alan P. , Billadeau Daniel D. , Mukhopadhyay Debabrata
Published: April 2023

The Supplementary Information includes kinase profile of 9-ING-41; IC50 values of 9-ING-41 and Staurosporine in selected eleven kinases and physicochemical properties, biological activity, PK parameters and preliminary ADME/Tox profile for 9-ING-41.
Supplementary Methods and Figure Legends from CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Authors: Salas Fragomeni Roberto A. , Chung Hye Won , Landesman Yosef , Senapedis William , Saint-Martin Jean-Richard , Tsao Hensin , Flaherty Keith T. , Shacham Sharon , Kauffman Michael , Cusack James C.
Published: April 2023

Supplementary Methods and Figure Legends - PDF 133K, Supplementary methods and figure legends
Supplementary Figure 7 from CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Authors: Salas Fragomeni Roberto A. , Chung Hye Won , Landesman Yosef , Senapedis William , Saint-Martin Jean-Richard , Tsao Hensin , Flaherty Keith T. , Shacham Sharon , Kauffman Michael , Cusack James C.
Published: April 2023

Supplementary Figure 7 - PDF file, TP53 knockdown in A375 reduces the effect of CRM1 inhibition on A375 proliferation but not on caspase-3/7 activity
Supplementary Table 4A from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

XLSX - 5959K, Table S4. Gene expression tables and differentially expressed gene lists from GSK3 inhibitor mRNA-seq. A. Gene expression values (CPMkb) for all genes in each sample obtained by mRNA-seq.
Supplementary Figure 2 from GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling
Authors: Duffy David J. , Krstic Aleksandar , Schwarzl Thomas , Higgins Desmond G. , Kolch Walter
Published: April 2023

PDF - 186K, Figure S2. Additional Retinoic Acid (RA) and cell viability. A. The effect of increased RA concentration on MYC mRNA expression in 48h doxycycline and 24h RA treated SY5Y-MYCN cells, assayed by qPCR. B. Time course of NVP-BEZ235 (dual PI3K/mTOR inhibitor) treatment on viability across the different cell lines, as measured by MTS assays. C. The effect of various inhibitors on viability across the different cell lines, as measured by MTS assays after 48h of inhibitor treatment. D. Viability results for SY5Y-MYCN cells with and without doxycycline induction (72h) of ectopic MYCN expression, treated with inhibitors for 48h as measured by MTS assays.
Supplementary Figure 5 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Authors: Bailey Melanie L. , O'Neil Nigel J. , van Pel Derek M. , Solomon David A. , Waldman Todd , Hieter Philip
Published: April 2023

PDF file - 271K, Supp. Fig. 5- Representative images of 42MGBA and 42MGBA STAG2 KI DAPI-stained nuclei treated with increasing concentrations of olaparib for four days. Examples of micronuclei (MN), fragmented nuclei (FN) and chromatin bridges (CB) are shown.
Supplementary Figure 2 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Authors: Bailey Melanie L. , O'Neil Nigel J. , van Pel Derek M. , Solomon David A. , Waldman Todd , Hieter Philip
Published: April 2023

PDF file - 153K, Supp. Fig. 2- A) Clonogenic survival of 42MGBA cells after olaparib treatment. The graph represents 3 technical replicates. B) HCT116 cell lines expressing either control shRNA (shLUC) or one of two shRNAs against STAG2, were treated with the indicated concentrations of olaparib for 4 days and cell number was determined by nuclei counting. C) Western blot of STAG2 knockdown in HCT116 shRNA lines. D-E) STAG2-mutated and KI 42MGBA cells were treated with D) veliparib and E) rucaparib for 5 days and cell number was determined by nuclei counting.
Supplementary Figures 1 - 7, Table 1 from Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models
Authors: Benetatos Christopher A. , Mitsuuchi Yasuhiro , Burns Jennifer M. , Neiman Eric M. , Condon Stephen M. , Yu Guangyao , Seipel Martin E. , Kapoor Gurpreet S. , LaPorte Matthew G. , Rippin Susan R. , Deng Yijun , Hendi Mukta S. , Tirunahari Pavan K. , Lee Yu-Hua , Haimowitz Thomas , Alexander Matthew D. , Graham Martin A. , Weng David , Shi Yigong , McKinlay Mark A. , Chunduru Srinivas K.
Published: April 2023

PDF file - 1384KB, Supplemental Figure 1. Structure of biotinylated birinapant Supplemental Figure 2. Concentration-dependent degradation of GFP-cIAP1/2 by birinapant Supplemental Figure 3. Representative examples of data analysis from 111 cell line panel of birinapant in combination with TRAIL analyzed using the MacSynergy II program. Supplemental Figure 4. Cells which are sensitive to birinapant as a single agent produce TNF in response to birinapant treatment Supplemental Figure 5. Birinapant induces cell death as a single agent in a TNF-dependent manner Supplemental Figure 6. Preferential degradation of TRAF2-associated cIAP1 and cIAP2 by birinapant Supplemental Figure 7. Birinapant inhibits the degradation of IkappaBalpha in cells stimulated with TNF; Supplemental Table 1: Kd values of birinapant and Smac-AVPI peptide for IAP BIR domains.
Supplementary Figures 1 through 4 from Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells
Authors: Xie Xiaoming , Kong Yanan , Tang Hailin , Yang Lu , Hsu Jennifer L. , Hung Mien-Chie
Published: April 2023

PDF - 398K, Figure S1. Tissue distribution of CMV-Luc and AT-VISA-Luc in male BABL/c nu/nu mice not bearing tumors; Figure S2. In vitro killing effect of BikDD; Figure S3. AT-VISA-BikDD inhibits tumor growth more effectively than CMV-BikDD in LnCAP orthotopic model; Figure S4. The expression of BikDD of prostate tissues in normal male nude mice treated with CMV-BikDD, AT-VISA-BikDD, and controls.
Supplementary Figure 9 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Authors: Kai Kazuharu , Kondo Kimie , Wang Xiaoping , Xie Xuemei , Pitner Mary K. , Reyes Monica E. , Torres-Adorno Angie M. , Masuda Hiroko , Hortobagyi Gabriel N. , Bartholomeusz Chandra , Saya Hideyuki , Tripathy Debu , Sen Subrata , Ueno Naoto T.
Published: April 2023

Mitotic accumulation induced by KW-2450 in TNBC cells.
Supplementary Figure 8 from Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases
Authors: Kai Kazuharu , Kondo Kimie , Wang Xiaoping , Xie Xuemei , Pitner Mary K. , Reyes Monica E. , Torres-Adorno Angie M. , Masuda Hiroko , Hortobagyi Gabriel N. , Bartholomeusz Chandra , Saya Hideyuki , Tripathy Debu , Sen Subrata , Ueno Naoto T.
Published: April 2023

Mice body weights follow-up during KW-2450 treatment.
Supplementary Methods, Figures 1 - 5 from Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP
Authors: Xie Xuemei , Bartholomeusz Chandra , Ahmed Ahmed A. , Kazansky Anna , Diao Lixia , Baggerly Keith A. , Hortobagyi Gabriel N. , Ueno Naoto T.
Published: April 2023

PDF file - 357K, Supplementary Figure 1. Chemical structure of paclitaxel: (2α,4α,5β,7β,10β,13α)-4,10-bis(acetyloxy)-13-{(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyloxy}-1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate. Supplementary Figure 2. Overexpression of PEA-15 phosphorylated at both Ser104 and Ser116 enhanced the apoptotic effect of paclitaxel in ovarian cancer cells. Supplementary Figure 3. The addition of caspase 8 and 9 inhibitors reduced paclitaxel-induced apoptosis in SKOV3.ip1-AA and SKOV3.ip1-DD cells. Supplementary Figure 4. Quantification of SCLIP mRNA levels in SKOV3.ip1 stable cells. Supplementary Figure 5. SCLIP mediated paclitaxel resistance in ovarian cancer cells.
Supplementary Figure 1 from ABT-737 Promotes the Dislocation of ER Luminal Proteins to the Cytosol, Including Pseudomonas Exotoxin
Authors: Antignani Antonella , Sarnovsky Robert , FitzGerald David J.
Published: April 2023

PDF - 65K, Loading controls of the cytosol and membrane fractions for the western blot shown in Fig 4A.
Supplementary Methods from Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis
Authors: Swers Jeffery S. , Grinberg Luba , Wang Lin , Feng Hui , Lekstrom Kristen , Carrasco Rosa , Xiao Zhan , Inigo Ivan , Leow Ching Ching , Wu Herren , Tice David A. , Baca Manuel
Published: April 2023

PDF file - 95K
Supplementary Table 1 from The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Authors: Garon Edward B. , Finn Richard S. , Hamidi Habib , Dering Judy , Pitts Sharon , Kamranpour Naeimeh , Desai Amrita J. , Hosmer Wylie , Ide Susan , Avsar Emin , Jensen Michael Rugaard , Quadt Cornelia , Liu Manway , Dubinett Steven M. , Slamon Dennis J.
Published: April 2023

PDF - 47B, A tabular demonstration of the efficacy and tolerability of NVP-AUY922 in 32 mice carrying subcutaneous A549 or H1975 xenograft tumors randomized
Supplementary Figure 5 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Authors: Gross Matt I. , Demo Susan D. , Dennison Jennifer B. , Chen Lijing , Chernov-Rogan Tania , Goyal Bindu , Janes Julie R. , Laidig Guy J. , Lewis Evan R. , Li Jim , MacKinnon Andrew L. , Parlati Francesco , Rodriguez Mirna L.M. , Shwonek Peter J. , Sjogren Eric B. , Stanton Timothy F. , Wang Taotao , Yang Jinfu , Zhao Frances , Bennett Mark K.
Published: April 2023

PDF - 85K, Supplementary Figure S5. Induction of apoptotic cell death by CB-839.
Supplementary Figure 2 from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
Authors: Cheung Arthur Kwok Leung , Yan Ip Joseph Chok , Lung Hong Lok , Wu Jim Zhen , Tsao Sai Wah , Lung Maria Li
Published: April 2023

PDF file - 11187K, Representative images of IF staining of γ-tubulin (green) and DAPI (blue) in untreated, vehicle and drug-treated (200 nM Ro5203280 for 24 hours) HONE1 and NP460 cell lines.
Supplementary Table 2 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance
Authors: Lee Hannah H. , Leake Brenda F. , Teft Wendy , Tirona Rommel G. , Kim Richard B. , Ho Richard H.
Published: April 2023

SLCO1B3 Variants
Supplementary Table 1 from Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Authors: Acquaviva Jaime , Smith Donald L. , Jimenez John-Paul , Zhang Chaohua , Sequeira Manuel , He Suqin , Sang Jim , Bates Richard C. , Proia David A.
Published: April 2023

PDF file - 58K, Kinase inhibitors that cause >50% reduction in p-ERK levels in A375-VR cells.
Supplementary Figure 3 from Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Authors: Acquaviva Jaime , Smith Donald L. , Jimenez John-Paul , Zhang Chaohua , Sequeira Manuel , He Suqin , Sang Jim , Bates Richard C. , Proia David A.
Published: April 2023

PDF file - 1383K, Body weight changes.
Supplementary Figure Legends, Tables 1 - 3 from Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1
Authors: Asuthkar Swapna , Gogineni Venkateswara Rao , Rao Jasti S. , Velpula Kiran Kumar
Published: April 2023

PDF file - 96K, Supplementary Table 1: Site-directed mutagenesis, cloning and RT-PCR primers for the genes; Supplementary Table 2: Site-directed mutagenesis and RT-PCR primers for the genes; Supplementary Table 3: The ChIP specific FIH-1_promoter_R1-R8 primer sequences.
Supplementary Figure S5 from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Authors: Sia Kian Chuan , Huynh Hung , Chung Alexander Yaw Fui , Ooi London Lucien Peng Jin , Lim Kiat Hon , Hui Kam Man , Lam Paula Yeng Po
Published: April 2023

Supplementary Figure S5 - PDF file 609K, Functionality of AH-6CC-L2C in expressing yCD suicide gene in vitro. PLC/PRF/5 cells were infected with AH-6CC-L2C at MOI of 8 and treated with 2 mM of 5-FC for 6 days. Cell viability was normalized to untreated cells as 100%. Data were presented as mean plus-minus SEM, n = 3
Supplementary Data from NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition
Authors: Dodd Rebecca D. , Mito Jeffrey K. , Eward William C. , Chitalia Rhea , Sachdeva Mohit , Ma Yan , Barretina Jordi , Dodd Leslie , Kirsch David G.
Published: April 2023

Supplementary Data - PDF file 1112K, Supplementary Figures 1-6 and Supplementary Tables 1&2
Supplementary Figures S1 to S11 from Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Authors: Loganzo Frank , Tan Xingzhi , Sung Matthew , Jin Guixian , Myers Jeremy S. , Melamud Eugene , Wang Fang , Diesl Veronica , Follettie Maximillian T. , Musto Sylvia , Lam My-Hanh , Hu William , Charati Manoj B. , Khandke Kiran , Kim Kenny Sung Kyoo , Cinque Mike , Lucas Judy , Graziani Edmund , Maderna Andreas , O'Donnell Christopher J. , Arndt Kim T. , Gerber Hans-Peter
Published: April 2023

Supplementary Figures S1 to S11. Supplementary Figure S1: Schematic illustration of the approach used to create trastuzumab-maytansinoid ADC resistant cell lines. Supplementary Figure S2: Structures of payloads and ADCs. Supplementary Figure S3: 361-TM-resistant cells show differential responses to ADCs with modified linkers, payloads, and antibodies. Supplementary Figure S4: Ectoptic expression of Her2 in JIMT1-TM cells rescues sensitivity to TM-ADC. Supplementary Figure S5: Cell surface proteomic profiling of 361-TM resistant cells, with evidence of increased ABCC1. Supplementary Figure S6: Knockdown of ABCC1 (MRP1) in 361-TM cells sensitizes to ADCs. Supplementary Figure S7: Endosomal and lysosomal proteins altered in JIMT1-TM resistant cells as determined by proteomic profiling. Supplementary Figure S8: Immunoblot verification of elevated surface-associated proteins in JIMT1-TM resistant cells. Supplementary Figure S9: Co-localization analyses of ADC and lysosome via live-cell imaging. Supplementary Figure S10: Altered trafficking in JIMT1-TM cells are specific to TM-ADC and not transferrin receptor antibody. Supplementary Figure S11: LC-MRM analyses of released products from ADCs incubated with parental and resistant cell lines.
Supplementary Figure 3 from Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response
Authors: Cesca Marta , Morosi Lavinia , Berndt Alexander , Nerini Ilaria Fuso , Frapolli Roberta , Richter Petra , Decio Alessandra , Dirsch Olaf , Micotti Edoardo , Giordano Silvia , D'Incalci Maurizio , Davoli Enrico , Zucchetti Massimo , Giavazzi Raffaella
Published: April 2023

MALDI MSI images from the tumor models described in Fig. 4 and 5 of the Results and Discussion, were quantified for ion signal distribution.
Supplementary Table 2 from A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
Authors: Awazu Yoshiko , Nakamura Kazuhide , Mizutani Akio , Kakoi Yuichi , Iwata Hidehisa , Yamasaki Seiji , Miyamoto Naoki , Imamura Shinichi , Miki Hiroshi , Hori Akira
Published: April 2023

PDF File - 78K, In vivo antitumor activity of T-1840383 vs. the antitumor activity of selective inhibitors of c-Met or VEGFR.
Supplementary Figure Legends from Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
Authors: Awasthi Niranjan , Zhang Changhua , Schwarz Anna M. , Hinz Stefan , Schwarz Margaret A. , Schwarz Roderich E.
Published: April 2023

PDF - 33K, Legends for Supplementary Figures 1 through 6.
Supplementary Figure 3 from Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
Authors: Awasthi Niranjan , Zhang Changhua , Schwarz Anna M. , Hinz Stefan , Schwarz Margaret A. , Schwarz Roderich E.
Published: April 2023

PDF - 142K, Nude mice were subcutaneously injected with Panc-1 cells and therapy was started after 2 weeks. (A) Relative tumor growth is calculated by dividing the tumor volume at any time by the tumor volume at the start of treatment. (B) Net tumor growth was calculated by subtracting tumor volume on the first treatment day from that on the final day. Data are representative of mean values 9plus or minus) standard deviation from 6-8 mice per group.
Supplementary Figure 1 from Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
Authors: Awasthi Niranjan , Zhang Changhua , Schwarz Anna M. , Hinz Stefan , Schwarz Margaret A. , Schwarz Roderich E.
Published: April 2023

PDF - 202K, (A) NOD/SCID mice in survival study and (B) Athymic nude mice in local tumor growth study were intraperitoneally injected with AsPC-1 cells. Two weeks after tumor cell injection, mice were treated intraperitoneally with PBS (control), nab-paclitaxel (10 mg/kg, twice weekly), bevacizumab (10 μg per mouse, twice weekly) and sunitinib (20 mg/kg, 5 times weekly). Mouse body weight was measured twice a week. Data are representative of mean values (plus or minus) standard deviation from 6-8 mice per group.
Supplementary Figure 6 from Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells
Authors: Bardeleben Carolyne , Sharma Sanjai , Reeve Joseph R. , Bassilian Sara , Frost Patrick , Hoang Bao , Shi Yijiang , Lichtenstein Alan
Published: April 2023

PDF file - 76K, Cell cycle analysis of cells treated with PALA in the presence or absence of uridine.
Supplemental Tables 1 and 2 and Figures 1-3 from The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
Authors: Phadke Manali S. , Sini Patrizia , Smalley Keiran S.M.
Published: April 2023

Supplemental Tables 1 and 2 and Figures 1-3. Supplemental Table 1: Cell line resistance mechanisms Supplemental Table 2: Ic50 values for BI-847325 on the cell line panel Supplemental Figure 1: BI-847325 blocks the proliferation and induces apoptosis in BRAF-mutant melanoma Supplemental Figure 2: MEK and Aurora kinase inhibitors do not decrease expression of Mcl-1 and MEK. Supplemental Figure 3: Inhibition of the proteasome does not reverse the effects of BI-847325 upon MEK expression.
Supplementary Figure 5 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Figure 5 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Table 4 from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table 4. DNA damage cluster obtained from DAVID analysis on proteins upregulated upon exposure to radiation.
Supplementary Table 3 from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table 3. Proteins phosporylated to a lower extent after 2Gy of ionizing radiation in SW1573 MASTL knockdown cells in comparison to SW1573 control cells.
Supplementary Figure 1 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Figure 1 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Figure Legends from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Authors: Wang Wei , Wang Ying-Qing , Meng Tao , Yi Jun-Mei , Huan Xia-Juan , Ma Lan-Ping , Tong Lin-Jiang , Chen Yi , Ding Jian , Shen Jing-Kang , Miao Ze-Hong
Published: April 2023

PDF - 84K, Legends for Supplementary Figures.
Supplementary Figure 7 from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Authors: Wang Wei , Wang Ying-Qing , Meng Tao , Yi Jun-Mei , Huan Xia-Juan , Ma Lan-Ping , Tong Lin-Jiang , Chen Yi , Ding Jian , Shen Jing-Kang , Miao Ze-Hong
Published: April 2023

PDF - 636K, Whether MT189 induces the colocalization of JNK or p-JNK with α-tubulin was examined by confocal microscopy.
Supplementary Figure 2 from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Figure 2. Knockdowns of FOXM1 and MASTL achieved by siRNAs or shRNA constructs.
Supplementary Figure 4 from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Authors: Wang Wei , Wang Ying-Qing , Meng Tao , Yi Jun-Mei , Huan Xia-Juan , Ma Lan-Ping , Tong Lin-Jiang , Chen Yi , Ding Jian , Shen Jing-Kang , Miao Ze-Hong
Published: April 2023

PDF - 37K, MT189 inhibits the proliferation of HeLa and SMMC-7721 cells in a time- and concentration-dependent manner.
Supplementary Figure 2 from Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
Authors: Narita Yusuke , Okamoto Kiyoshi , Kawada Megumi Ikemori , Takase Kazuma , Minoshima Yukinori , Kodama Kotaro , Iwata Masao , Miyamoto Norimasa , Sawada Kohei
Published: April 2023

PDF - 164K, MAPK pathway inhibitory activity of the test compounds in G361.
Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Authors: Campbell Robert M. , Anderson Bryan D. , Brooks Nathan A. , Brooks Harold B. , Chan Edward M. , De Dios Alfonso , Gilmour Raymond , Graff Jeremy R. , Jambrina Enrique , Mader Mary , McCann Denis , Na Songqing , Parsons Stephen H. , Pratt Susan E. , Shih Chuan , Stancato Louis F. , Starling James J. , Tate Courtney , Velasco Juan A. , Wang Yong , Ye Xiang S.
Published: April 2023

PDF file - 43K, Effect of LY2228820 on MK2 phosphorylation in mouse peripheral blood mononuclear cells (PBMC) and from patients with multiple myeloma.
Supplementary Table 3 from Marine Sponge Cribrochalina vasculum Compounds Activate Intrinsic Apoptotic Signaling and Inhibit Growth Factor Signaling Cascades in Non–Small Cell Lung Carcinoma
Authors: Zovko Ana , Viktorsson Kristina , Hååg Petra , Kovalerchick Dimitry , Färnegårdh Katarina , Alimonti Andrea , Ilan Micha , Carmeli Shmuel , Lewensohn Rolf
Published: April 2023

Supplementary Table 3: Compound 1 and compound 2-induced cytotoxicity in NSCLC U-1810 and normal diploid fibroblasts WI-38. Concentrations that induced 30 %, 50 % and 70 % (IC30, IC50 and 70) of cell viability reduction upon treatment with 1 or 2 for 24 h, 48 h or 72 h in NSCLC U-1810 and normal diploid fibroblasts WI-38 are given. The Area under the dose-response curve (AUC) is calculated for each treatment. The data presented is based on calculation from 3 independent biological replicates and the entire growth curves are shown in Supplementary Figure S2.
Supplementary Figure 1 from Ponatinib Induces Apoptosis in Imatinib-Resistant Human Mast Cells by Dephosphorylating Mutant D816V KIT and Silencing β-Catenin Signaling
Authors: Jin Bei , Ding Ke , Pan Jingxuan
Published: April 2023

PDF file - 134KB, The analysis of KIT mutation.
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
Authors: Dermawan Josephine Kam Tai , Gurova Katerina , Pink John , Dowlati Afshin , De Sarmishtha , Narla Goutham , Sharma Neelesh , Stark George R.
Published: April 2023

Supplementary figure S2